ReviewPLoS pathogens2025
Tecovirimat: A journey from discovery to mechanistic insights in poxvirus inhibition.
Review in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- An integrated review of monkeypox: from pathogen and epidemiology to diagnostics, control, and challenges.Emerging microbes & infections · 2026Review
- An experimentally validated structure-based computational framework for humanisation of anti-orthopoxvirus antibodies.EBioMedicine · 2026Article
- Piceatannol as a potential antiviral agent against vaccinia virus at multiple stages.Frontiers in microbiology · 2026Article
- Disulfiram inhibits poxvirus extracellular virus production by targeting the palmitoylation sites on F13.Microbiology spectrum · 2025Article
- Vimig: The virus-induced migrasome as a novel mechanism for viral transmission and communication.PLoS pathogens · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Tecovirimat (ST-246 or TPOXX) is an antiviral agent developed as part of a U.S. biodefense initiative aimed at addressing Orthopoxvirus infections, including smallpox and mpox. Although smallpox was declared eradicated in 1980, the potential for its reemergence as a biothreat persists due to illegal stockpiling and the possibility of laboratory synthesis. The F13 protein, which plays a critical role in the formation of extracellular viral particles, serves as the primary target for tecovirimat, inhibiting the transition from intracellular mature viruses (IMVs) to intracellular enveloped viruses (IEVs). Recent research indicates that tecovirimat stabilizes F13 homodimers as a molecular glue, effectively disrupting viral wrapping processes. However, the identification of tecovirimat-resistant mutations, particularly in immunocompromised individuals, highlights the urgent need for ongoing monitoring and the development of next-generation antiviral therapies. Investigating the structural dynamics of F13 and its interactions with tecovirimat may provide crucial insights into overcoming resistance mechanisms and improving therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.